UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.
Search Articles
Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, ISSN 1341-321X, 2015, Volume 22, Issue 1, pp. 1 - 13
Hematology, Oncology and Palliative Medicine | Infection | Anaerobes | Antimicrobial resistance | Antibiotics | Bacteroides fragilis | Pharmacology & Pharmacy | Infectious Diseases | Life Sciences & Biomedicine | Science & Technology | Cefoxitin - therapeutic use | Penicillins - therapeutic use | Bacterial Infections - drug therapy | Humans | Minocycline - analogs & derivatives | Anti-Infective Agents - therapeutic use | Drug Resistance, Bacterial | Chloramphenicol - therapeutic use | Bacteria, Anaerobic - pathogenicity | Clindamycin - therapeutic use | Carbapenems - therapeutic use | Metronidazole - therapeutic use | Minocycline - therapeutic use | beta-Lactamase Inhibitors - therapeutic use | Bacterial Infections - microbiology | Bacteria, Anaerobic - growth & development | Index Medicus
Journal Article
American journal of respiratory and critical care medicine, ISSN 1073-449X, 11/2009, Volume 180, Issue 9, pp. 896 - 902
Treatment outcome | Lung diseases | Mycobacterium abscessus | Atypical mycobacteria | Respiratory System | Life Sciences & Biomedicine | Critical Care Medicine | General & Internal Medicine | Science & Technology | Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy | Pharmacology. Drug treatments | Biological and medical sciences | Intensive care medicine | Medical sciences | Antibacterial agents | Antibiotics. Antiinfectious agents. Antiparasitic agents | Sputum - microbiology | Lung - microbiology | Cefoxitin - therapeutic use | Lung Diseases - microbiology | Humans | Middle Aged | Male | Tomography, X-Ray Computed | Lung - diagnostic imaging | Lung Diseases - drug therapy | Anti-Bacterial Agents - therapeutic use | Sputum - drug effects | Liver - drug effects | Mycobacterium Infections, Nontuberculous - microbiology | Adult | Female | Anti-Bacterial Agents - adverse effects | Retrospective Studies | Drug Therapy, Combination | Neutropenia - chemically induced | Chemical and Drug Induced Liver Injury - etiology | Doxycycline - adverse effects | Ciprofloxacin - adverse effects | Nontuberculous Mycobacteria - drug effects | Clarithromycin - adverse effects | Doxycycline - therapeutic use | Ciprofloxacin - therapeutic use | Anti-Infective Agents - therapeutic use | Treatment Outcome | Clarithromycin - therapeutic use | Thrombocytopenia - chemically induced | Nontuberculous Mycobacteria - isolation & purification | Amikacin - adverse effects | Amikacin - therapeutic use | Lung - drug effects | Cefoxitin - adverse effects | Mycobacterium Infections, Nontuberculous - drug therapy | Index Medicus | Abridged Index Medicus
Journal Article
JAMA surgery, ISSN 2168-6254, 05/2016, Volume 151, Issue 5, pp. 432 - 439
Life Sciences & Biomedicine | Surgery | Science & Technology | Perioperative Care | Cefoxitin - therapeutic use | Enterococcus faecalis - drug effects | Patient Readmission | Escherichia coli - drug effects | Humans | Drug Resistance, Bacterial | Sulbactam - therapeutic use | Male | Antibiotic Prophylaxis | Pancreaticoduodenectomy - adverse effects | Microbial Sensitivity Tests | Anti-Bacterial Agents - therapeutic use | Streptococcus pneumoniae - isolation & purification | Surgical Wound Infection - drug therapy | Metronidazole - therapeutic use | Bile - microbiology | Female | Ampicillin - therapeutic use | Streptococcus pneumoniae - drug effects | Cefazolin - therapeutic use | Staphylococcus aureus - isolation & purification | Surgical Wound Infection - prevention & control | Enterococcus faecalis - isolation & purification | Home Care Services | Escherichia coli - isolation & purification | Anti-Bacterial Agents - pharmacology | Surgical Wound Infection - microbiology | Staphylococcus aureus - drug effects | Stents - adverse effects
Journal Article
Molecules (Basel, Switzerland), ISSN 1420-3049, 12/2019, Volume 24, Issue 24, p. 4511
Biochemistry & Molecular Biology | Physical Sciences | Chemistry | Life Sciences & Biomedicine | Chemistry, Multidisciplinary | Science & Technology | Cell Line | Mycobacterium abscessus - classification | Thiostrepton - pharmacology | Humans | Thiostrepton - therapeutic use | Zebrafish | Dose-Response Relationship, Drug | Microbial Sensitivity Tests | Anti-Bacterial Agents - therapeutic use | Macrophages - metabolism | Animals | Mycobacterium Infections, Nontuberculous - microbiology | Anti-Bacterial Agents - chemistry | Mycobacterium Infections, Nontuberculous - metabolism | Inflammation Mediators - metabolism | Macrophages - drug effects | Anti-Bacterial Agents - pharmacology | Molecular Structure | Mycobacterium abscessus - genetics | Mycobacterium abscessus - drug effects | Cytokines - biosynthesis | Macrophages - immunology | Mycobacterium Infections, Nontuberculous - drug therapy | Disease Models, Animal | Clarithromycin | Antimicrobial activity | Amikacin | Body piercing | Infections | Macrophages | Drug resistance | Cancer therapies | Antiinfectives and antibacterials | Lipopolysaccharides | Streptococcus infections | Tumor necrosis factor-TNF | Cytokines | β-Lactam antibiotics | Staphylococcus infections | Antimicrobial agents | Thorax | Tumor necrosis factor-α | Cefoxitin | Gene expression | Infectious diseases | Tuberculosis | Thiostrepton | Interleukin 10 | Monoclonal antibodies | Binding sites | Imipenem | Index Medicus
Journal Article
American journal of respiratory and critical care medicine, ISSN 1073-449X, 02/2011, Volume 183, Issue 3, pp. 405 - 410
Mycobacterium massiliense | Treatment outcome | Clarithromycin | Mycobacterium abscessus | Nontuberculous mycobacteria | Respiratory System | Life Sciences & Biomedicine | Critical Care Medicine | General & Internal Medicine | Science & Technology | Biological and medical sciences | Intensive care medicine | Emergency and intensive care: metabolism and nutrition disorders. Enteral and parenteral nutrition | Medical sciences | Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy | Sputum - microbiology | Cefoxitin - therapeutic use | Nontuberculous Mycobacteria - drug effects | Humans | Middle Aged | Drug Resistance, Bacterial | Male | Treatment Outcome | Clarithromycin - therapeutic use | Mycobacterium Infections, Nontuberculous - diagnosis | Microbial Sensitivity Tests | Amikacin - therapeutic use | Mycobacterium Infections, Nontuberculous - microbiology | Antibiotics, Antitubercular - therapeutic use | Female | Retrospective Studies | Drug Therapy, Combination | Mycobacterium Infections, Nontuberculous - drug therapy | Index Medicus | Abridged Index Medicus
Journal Article
Letters in applied microbiology, ISSN 0266-8254, 01/2016, Volume 62, Issue 1, pp. 84 - 90
community UTI | uropathogenic Escherichia coli | virulence | antimicrobial resistance | children | phylogenetic group | Phylogenetic group | Uropathogenic Escherichia coli | Antimicrobial resistance | Children | Community UTI | Virulence | Life Sciences & Biomedicine | Microbiology | Biotechnology & Applied Microbiology | Science & Technology | Escherichia coli Infections - drug therapy | Cefoxitin - therapeutic use | Virulence Factors - genetics | Humans | Escherichia coli Infections - microbiology | Chloramphenicol - therapeutic use | Phylogeny | Urinary Tract Infections - drug therapy | Cephalosporins - therapeutic use | Microbial Sensitivity Tests | Anti-Bacterial Agents - therapeutic use | Uropathogenic Escherichia coli - drug effects | Uropathogenic Escherichia coli - isolation & purification | Uropathogenic Escherichia coli - pathogenicity | Drug Resistance, Multiple, Bacterial | Escherichia coli Proteins - genetics | Urinary Tract Infections - microbiology | Child | Ceftazidime - therapeutic use | Republic of Korea | Drug resistance in microorganisms | Analysis | Urinary tract infections | Virulence (Microbiology) | Health aspects | Antibacterial agents | Index Medicus
Journal Article
Antimicrobial Agents and Chemotherapy, ISSN 0066-4804, 03/2012, Volume 56, Issue 3, pp. 1376 - 1381
Pharmacology & Pharmacy | Life Sciences & Biomedicine | Microbiology | Science & Technology | Urinary tract. Prostate gland | Infectious diseases | Bacterial diseases | Human bacterial diseases | Urinary system involvement in other diseases. Miscellaneous | Pharmacology. Drug treatments | Nephrology. Urinary tract diseases | Biological and medical sciences | Medical sciences | Bacterial diseases of the urinary system | Antibiotics. Antiinfectious agents. Antiparasitic agents | Conjugation, Genetic | Imipenem - therapeutic use | Cefoxitin - therapeutic use | Carbapenems - administration & dosage | Escherichia coli - drug effects | Humans | Ceftriaxone - pharmacology | Bacterial Load - drug effects | Cefoxitin - pharmacology | Microbial Sensitivity Tests | Anti-Bacterial Agents - therapeutic use | Carbapenems - pharmacology | beta-Lactamases - genetics | Ceftriaxone - administration & dosage | Female | Urinary Tract Infections - microbiology | Urinary Bladder - microbiology | beta-Lactamases - metabolism | Disease Models, Animal | Escherichia coli Infections - drug therapy | Imipenem - administration & dosage | Kidney - drug effects | Cefoxitin - administration & dosage | Drug Administration Schedule | Escherichia coli Infections - microbiology | Mutation Rate | Imipenem - pharmacology | Urinary Tract Infections - drug therapy | Kidney - microbiology | beta-Lactams - pharmacology | Animals | Ceftriaxone - therapeutic use | Carbapenems - therapeutic use | Escherichia coli - genetics | Plasmids | Urinary Bladder - drug effects | Anti-Bacterial Agents - pharmacology | Mice | beta-Lactams - therapeutic use | Anti-Bacterial Agents - administration & dosage | beta-Lactams - administration & dosage | Index Medicus | Experimental Therapeutics
Journal Article
Clinical infectious diseases, ISSN 1058-4838, 5/2014, Volume 58, Issue 9, pp. 1287 - 1296
Microbial sensitivity tests | Cephalosporins | Penicillin | Methicillin resistant staphylococcus aureus | Infections | Skin | Joints | Staphylococcus | Staphylococcus aureus | Blood | MEDICAL MICROBIOLOGY | β-lactams and Staphylococcus | CLSI breakpoints | Staphylococcus susceptibility | Infectious Diseases | Immunology | Life Sciences & Biomedicine | Microbiology | Science & Technology | Infectious diseases | Bacterial diseases | Human bacterial diseases | Pharmacology. Drug treatments | Staphylococcal infections, streptococcal infections, pneumococcal infections | Biological and medical sciences | Medical sciences | Antibacterial agents | Antibiotics. Antiinfectious agents. Antiparasitic agents | Cefoxitin - therapeutic use | Staphylococcal Infections - drug therapy | beta-Lactam Resistance | Penicillins - therapeutic use | United States | Humans | Oxacillin - pharmacology | Staphylococcus - drug effects | Oxacillin - therapeutic use | Cefoxitin - pharmacology | Cephalosporins - therapeutic use | Microbial Sensitivity Tests | Anti-Bacterial Agents - therapeutic use | beta-Lactams - pharmacology | Anti-Bacterial Agents - pharmacology | Penicillins - pharmacology | beta-Lactams - therapeutic use | Cephalosporins - pharmacology | United States Food and Drug Administration | Care and treatment | Oxacillin | Usage | Diagnosis | Index Medicus
Journal Article
Antimicrobial Agents and Chemotherapy, ISSN 0066-4804, 04/2011, Volume 55, Issue 4, pp. 1485 - 1493
Pharmacology & Pharmacy | Life Sciences & Biomedicine | Microbiology | Science & Technology | Biological and medical sciences | Medical sciences | Pharmacology. Drug treatments | Antibiotics. Antiinfectious agents. Antiparasitic agents | Cefoxitin - therapeutic use | Klebsiella pneumoniae - drug effects | Ceftazidime - pharmacology | Porins - metabolism | Molecular Sequence Data | Male | Phagocytosis - genetics | Genetic Complementation Test | Cefoxitin - pharmacology | Cephalosporins - therapeutic use | Microbial Sensitivity Tests | Virulence - genetics | Klebsiella pneumoniae - genetics | Klebsiella pneumoniae - metabolism | Cephalosporins - pharmacology | Thienamycins - therapeutic use | Phagocytosis - drug effects | Klebsiella Infections - drug therapy | Porins - genetics | Bacterial Proteins - genetics | Klebsiella Infections - genetics | Thienamycins - pharmacology | Sequence Analysis, DNA | Animals | Klebsiella pneumoniae - pathogenicity | Virulence - physiology | Bacterial Proteins - metabolism | Mice | Mice, Inbred BALB C | Drug Resistance, Multiple, Bacterial - genetics | Ceftazidime - therapeutic use | Index Medicus | Mechanisms of Resistance
Journal Article
The New England journal of medicine, ISSN 0028-4793, 05/2015, Volume 372, Issue 21, pp. 2039 - 2048
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Anti-Bacterial Agents - therapeutic use | Cefoxitin - therapeutic use | Pelvic Inflammatory Disease - drug therapy | Doxycycline - therapeutic use | Pelvic Inflammatory Disease - prevention & control | Humans | Infertility, Female - etiology | Pelvic Inflammatory Disease - diagnosis | Female | Pelvic Inflammatory Disease - etiology | Pregnancy | Birth control | Sexually transmitted diseases--STD | Pain | Womens health | Pathogenesis | Infertility | Infections | Pelvic inflammatory disease | Inflammatory diseases | Index Medicus | Abridged Index Medicus
Journal Article